论文部分内容阅读
目的:探讨拟线粒体促凋亡多肽N7(SmacN7)能否增加人卵巢癌细胞对顺铂的敏感性及其与Caspase-3表达的关系。方法:通过细胞增殖抑制率测定及平板克隆形成试验研究顺铂单独应用组(A组),50μg/L SmacN7+顺铂组(B组)、100μg/L SmacN7+顺铂组(C组)及200μg/L SmacN7+顺铂组(D组)的细胞增殖抑制率和细胞克隆形成率;采用细胞免疫化学法检测上述分组中Caspase-3的表达。结果:单独应用顺铂时,24、48、72 h的增殖抑制率分别为(6.12±1.16)%、(13.47±1.15)%及(28.91±1.08)%。SmacN7(50～200μg/L)联合顺铂应用时,随着SmacN7浓度的增加或作用时间的延长,细胞增殖抑制率明显增加,药物作用24、48、72 h后增殖抑制率分别为(9.34±1.78)%～(49.81±2.11)%、(25.24±2.11)%～(65.54±2.27)%、(44.45±1.21)%～(82.36±2.19)%。肿瘤细胞存活率明显降低,分别为(25.13±0.52)%、(21.17±0.55)%、(18.23±0.54)%和(15.27±0.56)%。SmacN7联合顺铂应用后,Caspase-3的表达比单独应用顺铂明显增加(P=0.000)。结论:SmacN7能够明显增加人卵巢癌细胞对顺铂的敏感性。
Objective: To investigate whether the mitochondrial apoptosis-inducing polypeptide N7 (SmacN7) can increase the sensitivity of human ovarian cancer cells to cisplatin and its relationship with the expression of Caspase-3. Methods: The cell proliferation inhibition rate and the plate clone formation test were used to study the effect of cisplatin alone (A group), 50μg / L SmacN7 + cisplatin group (B group), 100μg / L SmacN7 + Cisplatin group (C group) and 200μg / L SmacN7 + cisplatin group (D group) cell proliferation inhibition rate and cell clone formation rate; Caspase-3 expression in the above-mentioned group was detected by immunocytochemistry. Results: When cisplatin alone was used, the proliferation inhibition rates at 24, 48, and 72 h were (6.12 ± 1.16)%, (13.47 ± 1.15)% and (28.91 ± 1.08)%, respectively. SmacN7 (50 ~ 200μg / L) combined with cisplatin application, with the increase of SmacN7 concentration or prolongation of action time, cell proliferation inhibition rate increased significantly, the drug effect 24,48,72 h after proliferation inhibition rates were (9.34 ± 1.78% ~ (49.81 ± 2.11)%, (25.24 ± 2.11)% ~ (65.54 ± 2.27)%, (44.45 ± 1.21)% ~ (82.36 ± 2.19)% respectively. The survival rate of tumor cells was significantly lower (25.13 ± 0.52)%, (21.17 ± 0.55)%, (18.23 ± 0.54)% and (15.27 ± 0.56)%, respectively. After SmacN7 combined with cisplatin, the expression of Caspase-3 was significantly increased (P = 0.000) compared with cisplatin alone. Conclusion: SmacN7 can significantly increase the sensitivity of human ovarian cancer cells to cisplatin.